Evidence map›Paper›PMID 24951486›Full record

SynthesisHeart (British Cardiac Society)2014

Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials.

Ruairidh I R Martin, Oksana Pogoryelova, Mauro Santibáñez Koref, John P Bourke, M Dawn Teare, Bernard D Keavney

Open access · hybridAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Heart (British Cardiac Society), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 6 pooled it
12.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 6 syntheses or guidelines pooled it, 158 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS).Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2017
    Guideline
  5. Guideline
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Guideline for Chronic Coronary Syndrome - 2025.Arquivos brasileiros de cardiologia · 2025
    Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Heart rate reduction after genetic ablation of L-type CaFrontiers in cardiovascular medicine · 2023
    Article
  18. Article
  19. Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Ruairidh I R MartinInstitute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK Department of Cardiology, Freeman Hospital, Newcastle, UK.
Oksana PogoryelovaInstitute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.
Mauro Santibáñez KorefInstitute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.
John P BourkeDepartment of Cardiology, Freeman Hospital, Newcastle, UK.
M Dawn TeareSchool of Health and Related Research, University of Sheffield, Sheffield, UK.
Bernard D KeavneyInstitute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK Institute of Cardiovascular Sciences, University of Manchester, Manchester, UK.
Newcastle University · GBFreeman Hospital · GBUniversity of Sheffield · GB

Funding

British Heart Foundation FS/12/55/29695
6 · The paper itself

Abstract

objectiveTo quantify any risk of atrial fibrillation (AF) associated with ivabradine treatment by meta-analysis of clinical trial data.

methodsMedline, Embase, Web of Knowledge and the Cochrane central register of controlled trials were searched for double-blinded randomised controlled trials of ivabradine with a minimum follow-up period of 4 weeks. For studies where AF data were unpublished, safety data were obtained from the European Medicines Agency (EMeA) website and personal communications. Studies were appraised for risk of bias using components recommended by the Cochrane Collaboration. Meta-analyses were performed of relative risk of AF and absolute risk difference of AF per year of treatment. The main outcome measure was incident AF during the follow-up period.

resultsAF data were available from 11 studies: one from the published report, six from the EMeA and four from personal communications. Ivabradine treatment was associated with a relative risk of AF of 1.15 (95% CI 1.07 to 1.24, p=0.0027) among 21 571 patients in the meta-analysis. From this we estimated that the number needed to harm for ivabradine would be 208 (95% CI 122 to 667) per year of treatment.

conclusionsAF is a substantially more common side effect of ivabradine treatment than one patient in 10 000, the risk presently reported in the product literature. The incidence of AF has not routinely been reported in clinical trials of ivabradine.

Indexed as

Atrial FibrillationBenzazepinesAngina PectorisHeart FailureHumansIncidenceIvabradineRandomized Controlled Trials as TopicRisk AssessmentBenzazepinesIvabradine

Identifiers

PMID24951486
PMCPMC4174120
OpenAlexW2159461724

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.